Apellis Pharmaceuticals Inc Transmettre P/E

Quel est le Transmettre P/E de Apellis Pharmaceuticals Inc?

Le Transmettre P/E de Apellis Pharmaceuticals Inc est -11.54

Quelle est la définition de Transmettre P/E?



Le ratio prix à terme/bénéfice est le rapport entre le prix des actions d'une société et son bénéfice par action estimé pour les douze prochains mois.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Transmettre P/E des entreprises dans Health Care secteur sur NASDAQ par rapport à Apellis Pharmaceuticals Inc

Que fait Apellis Pharmaceuticals Inc?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Entreprises avec transmettre p/e similaire à Apellis Pharmaceuticals Inc